These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 8513454

  • 21. Antigenic variants isolated from a mutagen-treated guinea pig fibrosarcoma.
    Zbar B, Sukumar S, Tanio Y, Terata N, Hovis J.
    Cancer Res; 1984 Nov; 44(11):5079-85. PubMed ID: 6488168
    [Abstract] [Full Text] [Related]

  • 22. Tumor cell variants obtained by mutagenesis of a Lewis lung carcinoma cell line: immune rejection by syngeneic mice.
    Van Pel A, Georlette M, Boon T.
    Proc Natl Acad Sci U S A; 1979 Oct; 76(10):5282-5. PubMed ID: 291945
    [Abstract] [Full Text] [Related]

  • 23. Induction of highly immunogenic variants of Lewis lung carcinoma tumor by ultraviolet irradiation.
    Peppoloni S, Herberman RB, Gorelik E.
    Cancer Res; 1985 Jun; 45(6):2560-6. PubMed ID: 2580624
    [Abstract] [Full Text] [Related]

  • 24. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
    Chen PW, Ananthaswamy HN.
    J Immunol; 1993 Jul 01; 151(1):244-55. PubMed ID: 8326126
    [Abstract] [Full Text] [Related]

  • 25. Immunomodulation of glioma cells after gene therapy: induction of major histocompatibility complex class I but not class II antigen in vitro.
    Parsa AT, Chi JH, Hurley PT, Jeyapalan SA, Bruce JN.
    Neurosurgery; 2001 Sep 01; 49(3):681-8; discussion 688-9. PubMed ID: 11523680
    [Abstract] [Full Text] [Related]

  • 26. Reduced tumorigenicity of murine tumor cells secreting gamma-interferon is due to nonspecific host responses and is unrelated to class I major histocompatibility complex expression.
    Esumi N, Hunt B, Itaya T, Frost P.
    Cancer Res; 1991 Feb 15; 51(4):1185-9. PubMed ID: 1900037
    [Abstract] [Full Text] [Related]

  • 27. Down-regulation of transforming growth factor-beta and interleukin-10 secretion from malignant glioma cells by cytokines and anticancer drugs.
    Naganuma H, Sasaki A, Satoh E, Nagasaka M, Nakano S, Isoe S, Nukui H.
    J Neurooncol; 1998 Sep 15; 39(3):227-36. PubMed ID: 9821108
    [Abstract] [Full Text] [Related]

  • 28. Effects of IFN-gamma and interleukin-1beta on major histocompatibility complex antigen and intercellular adhesion molecule-1 expression by 9L gliosarcoma: relevance to its cytolysis by alloreactive cytotoxic T lymphocytes.
    Schiltz PM, Gomez GG, Read SB, Kulprathipanja NV, Kruse CA.
    J Interferon Cytokine Res; 2002 Dec 15; 22(12):1209-16. PubMed ID: 12581494
    [Abstract] [Full Text] [Related]

  • 29. [A novel experimental approach to immunotherapy against malignant brain tumor with the mouse IFN-gamma gene transfer].
    Nishihara K.
    Nihon Geka Hokan; 1989 Jan 01; 58(1):18-42. PubMed ID: 2508589
    [Abstract] [Full Text] [Related]

  • 30. Immunizations with IFNgamma secreting tumor cells can eliminate fully established and invasive rat gliomas.
    Janelidze S, Bexell D, Badn W, Darabi A, Smith KE, Fritzell S, Gunnarsson S, Milos P, Bengzon J, Salford LG, Siesjö P, Visse E.
    J Immunother; 2009 Jan 01; 32(6):593-601. PubMed ID: 19483650
    [Abstract] [Full Text] [Related]

  • 31. Retroviral transduction of interferon-gamma cDNA into a nonimmunogenic murine fibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor.
    Shiloni E, Karp SE, Custer MC, Shilyansky J, Restifo NP, Rosenberg SA, Mulé JJ.
    Cancer Immunol Immunother; 1993 Oct 01; 37(5):286-92. PubMed ID: 8402732
    [Abstract] [Full Text] [Related]

  • 32. Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line.
    Boon T, Kellermann O.
    Proc Natl Acad Sci U S A; 1977 Jan 01; 74(1):272-5. PubMed ID: 264681
    [Abstract] [Full Text] [Related]

  • 33. Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line.
    Boon T, Van Pel A.
    Proc Natl Acad Sci U S A; 1978 Mar 01; 75(3):1519-23. PubMed ID: 274738
    [Abstract] [Full Text] [Related]

  • 34. Therapeutic vaccination against malignant gliomas based on allorecognition and syngeneic tumor antigens: proof of principle in two strains of rat.
    Stathopoulos A, Samuelson C, Milbouw G, Hermanne JP, Schijns VE, Chen TC.
    Vaccine; 2008 Mar 25; 26(14):1764-72. PubMed ID: 18336964
    [Abstract] [Full Text] [Related]

  • 35. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas.
    Newcomb EW, Demaria S, Lukyanov Y, Shao Y, Schnee T, Kawashima N, Lan L, Dewyngaert JK, Zagzag D, McBride WH, Formenti SC.
    Clin Cancer Res; 2006 Aug 01; 12(15):4730-7. PubMed ID: 16899624
    [Abstract] [Full Text] [Related]

  • 36. CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum- or helper peptides in priming for skin test reactivity to a P815AB-related peptide.
    Grohmann U, Bianchi R, Fioretti MC, Fallarino F, Binaglia L, Uyttenhove C, Van Pel A, Boon T, Puccetti P.
    Eur J Immunol; 1995 Oct 01; 25(10):2797-802. PubMed ID: 7589074
    [Abstract] [Full Text] [Related]

  • 37. B7.1 expression by the weakly immunogenic F98 rat glioma does not enhance immunogenicity.
    Paul DB, Barth RF, Yang W, Shen GH, Kim J, Triozzi PL.
    Gene Ther; 2000 Jun 01; 7(12):993-9. PubMed ID: 10871746
    [Abstract] [Full Text] [Related]

  • 38. An experimental study of dendritic cells-mediated immunotherapy against intracranial gliomas in rats.
    Zhu X, Lu C, Xiao B, Qiao J, Sun Y.
    J Neurooncol; 2005 Aug 01; 74(1):9-17. PubMed ID: 16078102
    [Abstract] [Full Text] [Related]

  • 39. Expression of major histocompatibility complex antigens in squamous cell carcinomas of the head and neck: effects of interferon gene transfer.
    Arosarena OA, Baranwal S, Strome S, Wolf GT, Krauss JC, Bradford CR, Carey TE.
    Otolaryngol Head Neck Surg; 1999 May 01; 120(5):665-71. PubMed ID: 10229590
    [Abstract] [Full Text] [Related]

  • 40. IFN-gamma alters the pathology of graft rejection: protection from early necrosis.
    Halloran PF, Miller LW, Urmson J, Ramassar V, Zhu LF, Kneteman NM, Solez K, Afrouzian M.
    J Immunol; 2001 Jun 15; 166(12):7072-81. PubMed ID: 11390451
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.